Celldex Therapeutics Initiates Phase 1b Study of CDX-0159 in Chronic Spontaneous Urticaria
October 13 2020 - 8:01AM
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that
enrollment has opened and the first patient has been dosed in its
randomized, double-blind Phase 1b study of CDX-0159 in patients
with chronic spontaneous urticaria (CSU). CDX-0159 is a humanized
monoclonal antibody developed by Celldex that binds the KIT
receptor with high specificity and potently inhibits its activity.
The KIT receptor tyrosine kinase is expressed in a variety of
cells, including mast cells, which mediate inflammatory responses
such as hypersensitivity and allergic reactions. KIT signaling
controls the differentiation, tissue recruitment, survival and
activity of mast cells. As previously presented, CDX-0159
demonstrated a favorable safety profile as well as profound and
durable reductions of plasma tryptase, indicative of systemic mast
cell ablation in a Phase 1a single dose, healthy volunteer study.
“We believe the profound decreases in plasma tryptase
demonstrated in our Phase 1a study suggest CDX-0159 has significant
potential as a disease-modifying therapeutic for mast cell driven
disorders,” said Diane C. Young, MD, Senior Vice President and
Chief Medical Officer of Celldex Therapeutics. “This latest study
will build on prior results as we seek to establish the safety and
potential clinical benefit of multi-dosing in a disease setting
fundamentally driven by mast cells—CSU. In the coming weeks, we
will further expand these efforts, initiating a second Phase 1b
study in chronic inducible urticaria.”
The Phase 1b study is a randomized, double-blind,
placebo-controlled clinical trial designed to assess the safety of
multiple ascending doses of CDX-0159 in patients with CSU who
remain symptomatic despite treatment with antihistamines. Secondary
and exploratory objectives include pharmacokinetic and
pharmacodynamic assessments, including measurement of tryptase and
stem cell factor levels and clinical activity outcomes (impact on
urticaria symptoms, disease control, clinical response) as well as
quality of life assessments. The study is expected to enroll
approximately 40 patients with CSU across four cohorts (8 CDX-0159;
2 placebo). CDX-0159 dosing for each cohort is as follows:
- Cohort 1 - 0.5 mg/kg Q 4 weeks;
- Cohort 2 - 1.5 mg/kg Q 4 weeks;
- Cohort 3 – 3 mg/kg Q 8 weeks; and,
- Cohort 4 – 4.5 mg/kg Q 8 weeks.
CDX-0159 will be administered intravenously as add on treatment
to H1-antihistamines, either alone or in combination with
H2-antihistamines and/or leukotriene receptor agonists.
More information about this study is available on
www.clinicaltrials.gov (Identifier: NCT04538794). Results from the
study are expected in the second half of 2021.
CSU is one of the most frequent dermatologic diseases with a
prevalence of 0.5-1% of the total population (up to 3.2M in the
US). Mast cell activation drives disease through the release of
histamines, leukotrienes and chemokines, resulting in episodes of
itchy hives, swelling and inflammation of the skin that can go on
for years or even decades. Currently approved therapies target
symptomatic relief. About 50% of patients with CSU achieve
symptomatic control with antihistamines or leukotriene receptor
antagonists. Omalizumab, an IgE inhibitor, provides relief for
roughly half of the remaining antihistamine/leukotriene refractory
patients. Celldex believes that CDX-0159 has significant potential
to interfere with mast cells at multiple steps upstream of current
treatments, which, in turn, could be disease modifying for
patients.
About CDX-0159CDX-0159 is a
monoclonal antibody that binds the KIT receptor with high
specificity and potently inhibits its activity. The KIT receptor
tyrosine kinase is expressed in a variety of cells, including mast
cells, which mediate inflammatory responses such as
hypersensitivity and allergic reactions. KIT signaling controls the
differentiation, tissue recruitment, survival and activity of mast
cells. Celldex is currently studying CDX-0159 in chronic
urticarias. Currently approved therapies for chronic urticarias
target symptomatic relief. Celldex believes that CDX-0159 has
significant potential to interfere with mast cells at multiple
steps upstream of current treatments, which, in turn, could be
disease modifying for patients. In addition, Celldex is also
evaluating additional opportunities in other mast cell driven
diseases where CDX-0159’s potency and high specificity for KIT
could be important.About Celldex Therapeutics,
Inc.Celldex is a clinical stage biotechnology company
dedicated to developing monoclonal and bispecific antibodies that
address devastating diseases for which available treatments are
inadequate. Our pipeline includes antibody-based therapeutics which
have the ability to engage the human immune system and/or directly
affect critical pathways to improve the lives of patients with
inflammatory diseases and many forms of cancer.
Forward Looking Statement This release contains
"forward-looking statements" made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
These statements are typically preceded by words such as
"believes," "expects," "anticipates," "intends," "will," "may,"
"should," or similar expressions. These forward-looking statements
reflect management's current knowledge, assumptions, judgment and
expectations regarding future performance or events. Although
management believes that the expectations reflected in such
statements are reasonable, they give no assurance that such
expectations will prove to be correct or that those goals will be
achieved, and you should be aware that actual results could differ
materially from those contained in the forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to, our ability to
successfully complete research and further development and
commercialization of Company drug candidates; the effects of the
outbreak of COVID-19 on our business and results of operations; the
uncertainties inherent in clinical testing and accruing patients
for clinical trials; our limited experience in bringing programs
through Phase 3 clinical trials; our ability to manage and
successfully complete multiple clinical trials and the research and
development efforts for our multiple products at varying stages of
development; the availability, cost, delivery and quality of
clinical and commercial grade materials produced by our own
manufacturing facility or supplied by contract manufacturers, who
may be our sole source of supply; the timing, cost and uncertainty
of obtaining regulatory approvals; the failure of the market for
the Company's programs to continue to develop; our ability to
protect the Company's intellectual property; the loss of any
executive officers or key personnel or consultants; competition;
changes in the regulatory landscape or the imposition of
regulations that affect the Company's products; our ability to
continue to obtain capital to meet our long-term liquidity needs on
acceptable terms, or at all, including the additional capital which
will be necessary to complete the clinical trials that we have
initiated or plan to initiate; and other factors listed under "Risk
Factors" in our annual report on Form 10-K and quarterly reports on
Form 10-Q.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You are cautioned not to place
undue reliance on any forward-looking statements, which speak only
as of the date of this release. We have no obligation, and
expressly disclaim any obligation, to update, revise or correct any
of the forward-looking statements, whether as a result of new
information, future events or otherwise.
Company ContactSarah CavanaughSenior Vice
President, Corporate Affairs & AdministrationCelldex
Therapeutics, Inc.(781) 433-3161scavanaugh@celldex.com
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Apr 2023 to Apr 2024